小儿消积止咳口服液联合西药治疗儿童支气管哮喘临床效果的远期观察(1)
摘要 目的：探究小儿消积止咳口服液联合西药治疗儿童支气管哮喘临床效果的远期影响。方法：选取2018年1月至2019年6月合肥市第三人民医院收治的支气管哮喘患儿66例作为研究对象，按照随机数字表法随机分为观察组和对照组，每组33例，观察组在观察组基础上加用小儿消积止咳口服液，分组治疗3个月，对照组在常规治疗基础上给予布地奈德雾化吸入和孟鲁司特钠颗粒口服治疗;比较2组患儿的临床疗效及炎性反应、免疫相关指标;院外随访6个月，复查并比较上述指标变化。结果：观察组的治疗总有效率明显优于对照组(P<0.05);分组治疗3个月，观察组患儿EOS百分比、IgA、IgE及IgG水平明显改善且优于对照组及治疗前(P<0.05);随访6个月观察组EOS百分比、IgA、IgE和IgG水平明显优于对照组(P<0.05)，复发率略低于对照组(P>0.05)。结论：小儿消积止咳口服液联合孟鲁司特钠及布地奈德可长期降低支气管哮喘患儿炎性反应水平并改善其免疫功能，提高临床疗效，一定程度上降低复发率。
关键词 小儿消积止咳口服液;孟鲁司特钠;布地奈德;儿童哮喘
Abstract Objective：To explore the long-term effects of Xiaoer Xiaoji Oral Liquid combined with Western medicine on children with bronchial asthma.Methods：A total of 66 children with bronchial asthma treated in Hefei Third People′s Hospital from January 2018 to June 2019 were randomly divided into a contro group(n=33)and an observation group(n=33)according to random number table.In the control group，budesonide aerosol inhalation and montelukast sodium granules were given orally.The observation group was treated with Xiaoer Xiaoji Oral Liquid on the basis of the control group.The groups were treated for 3 months.Clinical efficacy，and immune related indicators were compared; In the follow-up for 6 months outside the hospital，the above indicators were compared.Results：The total effective rate in the observation group was significantly better than that in the control group(P<0.05).After 3 months of group treatment，the percentage of EOS，levels of IgA，IgE and IgG in the observation group were significantly improved and better than those in the control group and before treatment(P<0.05); EOS percentage，IgA，IgE，and IgG levels in the observation group were significantly better than those in the control group(P<0.05)，and the recurrence rate was slightly lower than that in the control group(P>0.05).Conclusion：Xiaoer Xiaoji Oral Liquid combined with montelukast sodium and budesonide can reduce the inflammation level，improve the immune function of children with bronchial asthma in a long-term，improve the clinical efficacy，and reduce the recurrence rate to a certain extent.
Keywords Xiaoer Xiaoji Oral Liquid; Montelukast sodium; Budesonide; Asthma in children
中圖分类号：R256.12;R272;R2-031;R725.6文献标识码：Adoi：10.3969/j.issn.1673-7202.2020.11.020
儿童支气管哮喘属于一种气道慢性炎性反应性疾病，其发病率在近20年以每10年20%～50%的比例持续增长[1]，且临床复发率较高，但目前临床控制效果并不理想。目前儿童哮喘的常规治疗方案为布地奈德联合孟鲁司特钠，其中布地奈德为糖皮质激素，可抑制气道炎性反应，孟鲁司特钠可阻断白三烯受体，间接发挥抗炎、缓解气道痉挛，改善哮喘症状的作用，但是这种联合治疗的长期控制效果并不十分理想。小儿消积止咳口服液是一种中药制剂，其具有清热宣肺止咳的功效，药力相对缓和，可减轻痰液分泌[2]，因此本研究探讨了小儿消积止咳口服液联合孟鲁司特钠及布地奈德治疗儿童支气管哮喘对临床及其对免疫指标的远期影响。, 百拇医药(周璇 葛灿侠 陈羽 钱晓君 王艳玲)
关键词 小儿消积止咳口服液;孟鲁司特钠;布地奈德;儿童哮喘
Abstract Objective：To explore the long-term effects of Xiaoer Xiaoji Oral Liquid combined with Western medicine on children with bronchial asthma.Methods：A total of 66 children with bronchial asthma treated in Hefei Third People′s Hospital from January 2018 to June 2019 were randomly divided into a contro group(n=33)and an observation group(n=33)according to random number table.In the control group，budesonide aerosol inhalation and montelukast sodium granules were given orally.The observation group was treated with Xiaoer Xiaoji Oral Liquid on the basis of the control group.The groups were treated for 3 months.Clinical efficacy，and immune related indicators were compared; In the follow-up for 6 months outside the hospital，the above indicators were compared.Results：The total effective rate in the observation group was significantly better than that in the control group(P<0.05).After 3 months of group treatment，the percentage of EOS，levels of IgA，IgE and IgG in the observation group were significantly improved and better than those in the control group and before treatment(P<0.05); EOS percentage，IgA，IgE，and IgG levels in the observation group were significantly better than those in the control group(P<0.05)，and the recurrence rate was slightly lower than that in the control group(P>0.05).Conclusion：Xiaoer Xiaoji Oral Liquid combined with montelukast sodium and budesonide can reduce the inflammation level，improve the immune function of children with bronchial asthma in a long-term，improve the clinical efficacy，and reduce the recurrence rate to a certain extent.
Keywords Xiaoer Xiaoji Oral Liquid; Montelukast sodium; Budesonide; Asthma in children
中圖分类号：R256.12;R272;R2-031;R725.6文献标识码：Adoi：10.3969/j.issn.1673-7202.2020.11.020
儿童支气管哮喘属于一种气道慢性炎性反应性疾病，其发病率在近20年以每10年20%～50%的比例持续增长[1]，且临床复发率较高，但目前临床控制效果并不理想。目前儿童哮喘的常规治疗方案为布地奈德联合孟鲁司特钠，其中布地奈德为糖皮质激素，可抑制气道炎性反应，孟鲁司特钠可阻断白三烯受体，间接发挥抗炎、缓解气道痉挛，改善哮喘症状的作用，但是这种联合治疗的长期控制效果并不十分理想。小儿消积止咳口服液是一种中药制剂，其具有清热宣肺止咳的功效，药力相对缓和，可减轻痰液分泌[2]，因此本研究探讨了小儿消积止咳口服液联合孟鲁司特钠及布地奈德治疗儿童支气管哮喘对临床及其对免疫指标的远期影响。, 百拇医药(周璇 葛灿侠 陈羽 钱晓君 王艳玲)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 气管、支气管疾病 > 支气管哮喘